We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+31.78%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$232M
AUM Growth
+$30.7M
(+15%)
Cap. Flow
-$28.5M
Cap. Flow
% of AUM
-12.29%
Top 10 Holdings %
Top 10 Hldgs %
46.06%
Holding
89
New
6
Increased
22
Reduced
19
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wave Life Sciences
WVE
|
+$5.79M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$2.82M |
| 3 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$2.27M |
| 4 |
MRSN
Mersana Therapeutics
MRSN
|
+$2.03M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
+$2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$25.4M |
| 2 |
NXTM
NxStage Medical Inc.
NXTM
|
+$8.93M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$2.88M |
| 4 |
argenx
ARGX
|
+$2.66M |
| 5 |
Kura Oncology
KURA
|
+$1.73M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.57% |
| 2 | Miscellaneous | 5.43% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$145M
| $26.7M | 11.51% |
13,680,554
| – | – |
|
|
SAGE
2
DELISTED
Sage Therapeutics
SAGE
| $19.7M | 8.49% |
123,806
+19,500
| +19% | +$2.82M |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $9.58M | 4.13% |
119,718
+27,027
| +29% | +$2M |
|
4
AtriCure
ATRC
$2.47B
| $8.54M | 3.68% |
318,729
| – | – |
|
|
ALDR
5
DELISTED
Alder Biopharmaceuticals
ALDR
| $7.79M | 3.36% |
571,013
+175,000
| +44% | +$2.27M |
|
|
6
Wave Life Sciences
WVE
$993M
| $7.4M | 3.19% |
190,554
+142,654
| +298% | +$5.79M |
|
|
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
| $7.21M | 3.11% |
151,770
+10,000
| +7% | +$440K |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $7.14M | 3.08% |
129,764
-14,000
| -10% | -$666K |
|
9
iShares Biotechnology ETF
IBB
$10.5B
| $6.87M | 2.96% |
61,400
-3,500
| -5% | -$384K |
|
10
Akebia Therapeutics
AKBA
$243M
| $5.86M | 2.53% |
715,538
| – | – |
|
|
LKFT
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
| $5.84M | 2.52% |
49,609
+8,000
| +19% | +$807K |
|
|
12
Ascendis Pharma A/S
ASND
$16.3B
| $5.22M | 2.25% |
44,380
-32,862
| -43% | -$2.88M |
|
13
Neurocrine Biosciences
NBIX
$15.7B
| $4.85M | 2.09% |
55,008
| – | – |
|
|
YARW
14
Yarrow Bioscience
YARW
$98.8M
| $4.71M | 2.03% |
167
+17
| +11% | +$408K |
|
|
15
argenx
ARGX
$64B
| $4.45M | 1.92% |
35,650
-22,650
| -39% | -$2.66M |
|
|
BLUE
16
DELISTED
bluebird bio
BLUE
| $4.25M | 1.83% |
2,084
| – | – |
|
|
ARNA
17
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.21M | 1.82% |
93,942
| – | – |
|
|
BHVN
18
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.12M | 1.78% |
80,000
| – | – |
|
19
BioCryst Pharmaceuticals
BCRX
$2.51B
| $4.06M | 1.75% |
498,415
+34,000
| +7% | +$291K |
|
20
DexCom
DXCM
$34.3B
| $3.85M | 1.66% |
129,352
-6,648
| -5% | -$234K |
|
|
CBAY
21
DELISTED
Cymabay Therapeutics
CBAY
| $3.7M | 1.6% |
278,811
-53,700
| -16% | -$571K |
|
22
ProQR Therapeutics
PRQR
$323M
| $3.63M | 1.56% |
261,521
-10,953
| -4% | -$164K |
|
23
Xenon Pharmaceuticals
XENE
$5.81B
| $3.36M | 1.45% |
330,667
+92,984
| +39% | +$788K |
|
24
Cytokinetics
CYTK
$10B
| $3.24M | 1.4% |
400,294
+214,468
| +115% | +$1.58M |
|
|
LMNX
25
DELISTED
Luminex Corp
LMNX
| $3.18M | 1.37% |
138,391
| – | – |
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, DAFNA Capital Management held 89 positions worth $232M, up 15% from $201M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
DAFNA Capital Management withdrew a net $28.5M in Q1 2019, closing 10 positions and reducing 19 holdings. Its most notable exit was Loxo Oncology, Inc, an estimated $25.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, DAFNA Capital Management opened a new position in Mersana Therapeutics worth $2.12M.
- DAFNA Capital Management's largest Q1 2019 buy was Mersana Therapeutics: 16,132 shares worth $2.12M.
- DAFNA Capital Management added most to Wave Life Sciences in Q1 2019, an estimated $5.79M increase.
- DAFNA Capital Management's biggest Q1 2019 reduction was Ascendis Pharma A/S, cutting an estimated $2.88M.
- DAFNA Capital Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $25.4M.
- DAFNA Capital Management's ten largest holdings make up 46% of its $232M portfolio in Q1 2019.
- DAFNA Capital Management opened 6 new positions and closed 10 in Q1 2019.
- DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $232M.
Based on DAFNA Capital Management's 13F filing for Q1 2019, filed 15 May 2019.